Northwestern Mutual Future Ventures, the corporate venture fund of multibillion-dollar financial management company Northwestern Mutual, has invested in a Japanese health diagnostics company and appears to be the first reported investment from the Milwaukee-based company’s second corporate venture fund.
In May, the company announced it had launched a second corporate venture capital fund, called Future Ventures Fund II, at $150 million. Future Ventures Fund I, which launched in 2017 at $50 million, is now fully committed.
Northwestern Mutual was one of five companies to invest in a $33 million, Series C funding round by Tokyo-based Atonarp Inc. Other investors in the round included Japan Post Investment Corp., SBI Investment Co. Ltd., and current investors The Innovation Network Corp. of Japan, which led the round, Japan’s Innovative Venture Fund, and an undisclosed medical equipment manufacturing company.
Deals from Northwestern Mutual’s Future Ventures Fund II were expected to range from $500,000 to $5 million, company officials previously said.
Atonarp has raised more than $61 million since 2014 to grow its artificial intelligence-based diagnostics platform that performs blood testing “with lab-quality accuracy but with real-time actionable data,” according to the company. Read the full story here.